SCHEMBL17386310

SCHEMBL17386310

COC(=O)c1ccccc1C(Br)Cc1cc(C)cc(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ HTT P42858 2/20 0.40
▸ TACR1 P25103 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ CFTR P13569 1/20 0.38
▸ SLC7A5 Q01650 1/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ CDC25B P30305 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17386084 0.78 CA1 (0.45) KDM4EMAPTTACR1GAAPOLB
SCHEMBL17386156 0.75 ALDH1A1 (0.52) KDM4EHSD17B10TSHRALDH1A1MAPT
SCHEMBL14565220 0.73 ALDH1A1 (0.51) KDM4EHSD17B10TSHRALDH1A1MAPT
SCHEMBL17385867 0.73 ALDH1A1 (0.50) KDM4EHSD17B10TSHRALDH1A1MAPT
SCHEMBL16191481 0.73 LDHA (0.50) KDM4EHSD17B10TSHRALDH1A1HPGD
SCHEMBL17386142 0.70 NPC1 (0.39) KDM4EHSD17B10TSHRALDH1A1MAPT
SCHEMBL17386143 0.70 NPC1 (0.39) KDM4EHSD17B10TSHRALDH1A1MAPT
SCHEMBL18828099 0.69 CA1 (0.46) KDM4EALDH1A1MAPTHPGDTACR1
SCHEMBL17385786 0.69 MAPT (0.38) KDM4EHSD17B10TSHRALDH1A1MAPT
SCHEMBL7171954 0.68 TSHR (0.53) KDM4EHSD17B10TSHRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2963027-B1 TRICYCLIC COMPOUND AND USE THEREOF TIUMBIO CO LTD (KR) 2018-12-26 — — EP disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 — — US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 — — US disclosed
EP-2963027-A1 TRICYCLIC COMPOUND AND USE THEREOF SK Chemicals Co., Ltd. (KR) 2016-01-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF GPR65, GPR119, GPR35 KDM4E 3682/4885HSD17B10 294/4885TSHR 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback